Page last updated: 2024-12-07

morphiceptin, n-me-phe(3)-

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Morphiceptin is a synthetic tetrapeptide analog of the opioid receptor-binding region of the opioid-like neuropeptide, endomorphin-1. It was synthesized to study the structure-activity relationships of opioid receptors, particularly the mu-opioid receptor, which is involved in pain perception, reward, and addiction. Morphiceptin is a potent and selective agonist for the mu-opioid receptor, exhibiting analgesic effects in animal models. It has been studied for its potential therapeutic applications in pain management, as well as for its role in understanding the mechanisms of opioid dependence and tolerance. Its high affinity for the mu-opioid receptor and its lack of intrinsic activity at other opioid receptors make it a valuable tool for studying the effects of mu-opioid receptor activation in a variety of contexts.'

morphiceptin, N-Me-Phe(3)-: RN given refers to D-prolinamide, all L-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID115335
CHEMBL ID283287
MeSH IDM0130418

Synonyms (32)

Synonym
pl 17
gtpl1671
pl-017
PDSP2_001552
pl017
83397-56-2
bdbm50140906
1-[2-[1-[2-amino-3-(4-hydroxyphenyl)-(2s)-propanoyl]-(5s)-dihydro-1h-5-pyrrolyl(methyl)carboxamido]-3-phenyl-(2s)-propanoyl]-(5r)-dihydro-1h-5-pyrrolecarboxamide
CHEMBL283287 ,
l-tyrosyl-l-prolyl-n-methyl-l-phenylalanyl-d-prolinamide
(2s)-1-[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]-n-[(2s)-1-[(2r)-2-carbamoylpyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]-n-methylpyrrolidine-2-carboxamide
morphiceptin, n-me-phe(3)-
tyrosyl-prolyl-n-methylphenlalanyl-prolinamide
morphiceptin, n-methylphenylalanine(3)-
3-n-me-phe-morphiceptin
tyr-pro-n-mephe-pro-nh2
pl 017
plo17
d-prolinamide, l-tyrosyl-l-prolyl-n-methyl-l-phenylalanyl-
(n-me-phe3,d-pro4)-beta-casomorphin(1-4)amide(bovine)
HY-P1338
CS-0029462
pl-017 tfa
tyr-pro-nmephe-d-pro-nh2
tyr-pro-mephe-d-pro-nh2
tyr-pro-nme-phe-d-pro-nh2
h-tyr-pro-n-me-phe-d-pro-nh2
(s)-1-((s)-2-amino-3-(4-hydroxyphenyl)propanoyl)-n-((s)-1-((r)-2-carbamoylpyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-yl)-n-methylpyrrolidine-2-carboxamide
Q27088408
ypfp
DTXSID401003384
tyrosyl-n-(1-{2-[hydroxy(imino)methyl]pyrrolidin-1-yl}-1-oxo-3-phenylpropan-2-yl)-n-methylprolinamide

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The dose-response curves of the antinociceptive effect of PL017 were shifted to the right with increasing doses of pertussis toxin."( Intrathecal pertussis toxin treatment attenuates opioid antinociception and reduces high-affinity state of opioid receptors.
Chang, KJ; Su, YF; Watkins, WD; Wong, CS, 1992
)
0.28
" The depressive effects induced by the mu agonist PL017 (5 micrograms), delta agonist DADLE (25 micrograms) and kappa agonist 66A-078 (1 microgram) were antagonized by CCK-8 within a dosage of 10 micrograms in a dose dependent manner."( [Cholecystokinin-octapeptide antagonizes the central depressive effect of opioid peptides in rats].
Han, JS; Mei, L, 1991
)
0.28
"5 microgram/hr) for 5 days caused 61- and 6-fold shifts to the right of the dose-response curves for PL-17 and DPDPE, respectively."( Interaction between highly selective mu and delta opioids in vivo at the rat spinal cord.
Chang, KJ; Leslie, JB; Russell, RD; Su, YF; Watkins, WD, 1986
)
0.27
" The slope of the analgesic dose-response curve for the highly specific delta agonist, cyclic [D-Penicillamine2, D-Penicillamine5]enkephalin (DPDPE), was significantly different (flatter) from those of mu agonists or DADLE."( Continuous intrathecal opioid analgesia: tolerance and cross-tolerance of mu and delta spinal opioid receptors.
Chang, KJ; Leslie, JB; Russell, RD; Su, YF; Watkins, WD, 1987
)
0.27
"01-micrograms dosage was associated with hyperactivity."( Behavioral effects of the mu-opioid peptide agonists DAMGO, DALDA, and PL017 on locomotor activities.
Meyer, ME, 1993
)
0.29
" However, [D-Pen2,D-Pen5]enkephalin (DPDPE), a delta 1-opioid receptor agonist, and [D-Ala2,Cys4]deltorphin, a delta 2-opioid receptor agonist, at doses which exhibit no intrinsic effects (10(-8) and 10(-7) M), shifted the dose-response curve for mu-opioid receptor-evoked adenosine release to the left in a dose-dependent manner."( Synergy between mu/delta-opioid receptors mediates adenosine release from spinal cord synaptosomes.
Cahill, CM; Sawynok, J; White, TD, 1996
)
0.29
" for 1, 3 or 5 days, using an escalating dosage paradigm (0."( Immunohistochemical evidence of down-regulation of mu-opioid receptor after chronic PL-017 in rats.
Elde, R; Han, KF; Law, PY; Loh, HH; Lue, WM; Tao, PL; Wang, SD, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Delta-type opioid receptorMus musculus (house mouse)IC50 (µMol)0.24300.00010.729810.0000AID148651
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1346364Human mu receptor (Opioid receptors)1983The Journal of pharmacology and experimental therapeutics, Nov, Volume: 227, Issue:2
Potent morphiceptin analogs: structure activity relationships and morphine-like activities.
AID1346364Human mu receptor (Opioid receptors)1998NIDA research monograph, Mar, Volume: 178Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
AID149862Inhibitory concentration for inhibition of Opioid receptor mu 1 induced contractions in guinea pig ileum (GPI) smooth muscle assays2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
AID148641In vitro inhibitory activity against delta opioid receptor using mouse vas deferens (MVD) assay1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
A topochemical approach to explain morphiceptin bioactivity.
AID224563In vitro inhibitory activity against mu opioid receptor using guinea pig ileum (GPI) assay1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
A topochemical approach to explain morphiceptin bioactivity.
AID150007Antagonism towards Opioid receptor mu 1 relative to PL-017 in guinea pig ileum (GPI) smooth muscle contraction assays; d = agonist effect was observed2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
AID148651Inhibitory concentration required for 50 percent inhibition of opioid receptor delta 1 induced contractions in mouse vas deferens (MVD) smooth muscle contraction assays2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
AID148801Antagonism of compound towards delta receptors was determined using DPDPE in mouse vas deferens (MVD) smooth muscle contraction assays; d = agonist effect was observed2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
AID234375Selectivity ratio is IC50 value of delta opioid receptor using mouse vas deferens (MVD) to that of mu opioid receptor using guinea pig ileum (GPI)1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
A topochemical approach to explain morphiceptin bioactivity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (94)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (20.21)18.7374
1990's68 (72.34)18.2507
2000's6 (6.38)29.6817
2010's1 (1.06)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.03 (24.57)
Research Supply Index4.57 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.03)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.05%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other94 (98.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]